MedTrace Logo

A Phase Ia Clinical Trial of HW241045

NCT07448194 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2026-03-04

No results posted yet for this study

Summary

This is a Phase Ia, randomized, double-blind, placebo-controlled study to assess the safety, tolerability and pharmacokinetic (PK) of HW241045 in healthy subjects following a single ascending dose.

Conditions

  • Healthy Volunteers
  • IPF

Interventions

DRUG

HW241045

Dose 1 to Dose 7

DRUG

Placebo

Dose 1 to Dose 7

Sponsors & Collaborators

  • Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-24
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07448194 on ClinicalTrials.gov